drugset / Trial / NCT02240290
Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled Tozadenant
Phase 1
Completed
6 enrolled
Biotie Therapies Inc.
PRA Health Sciences · collabTandem Labs · collabXceleron Inc · collab
NaSingle-groupOpen-labelBasic science
Summary
The purpose of the study is to investigate how tozadenant is absorbed, distributed, broken down and eliminated from the body. The compound to be administered will be radiolabeled. This enables the investigator to trace the compound in blood, urine, feces, expired air and track what happens to it.
Timeline
- Start
- 2013-09
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tozadenant | Small molecule | 0.074 mbq | Oral |
| Subject | Tozadenant | Small molecule | 240 mg | Oral |
Indications
No indication recorded.